Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status:
Unknown status
Trial end date:
2019-09-16
Target enrollment:
Participant gender:
Summary
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that causes the death of
30,000 affected individual every year. Complex nature and unknown pathogenesis of this
disease are 2 major reasons for failure of therapeutic interventions. Edaravone is a free
radical scavenger that slows down functional decline and prevents from disease progression in
ALS patients. FDA newly approved this drug in these patients (2017/5/5). In this study,
investigators aimed to assess the treatment effect of this newly approved drug in patients
with ALS in a representative Iranian population.